| 臺大學術典藏 |
2020-05-26T09:26:57Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C;Su W.-C;Yen C.-J;Hsu C.-H;Su W.-P;Yeh K.-H;Lu Y.-S;Cheng A.-L;Huang D.C.-L;Fritsch H;Voss F;Taube T;Chih-Hsin Yang; Lin C.-C; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
High prevalence of the BIM deletion polymorphism in young female breast cancer in an East Asian country
|
Chen I.-C; Wu P.-F; Kuo S.-H; Chen C.-J; Lu Y.-S; Cheng A.-L.; Cheng A.-L.;Lu Y.-S;Chen C.-J;Kuo S.-H;Wu P.-F;Chen I.-C;Chen W.-W;Kuo K.-T;Hsiung C.-N;Chang D.-Y;Kuo W.-H;Chih-Hsin Yang;Huang C.-S;Lee J.-H;Shen C.-Y;Lin C.-H; Lin C.-H; Shen C.-Y; Lee J.-H; Huang C.-S; CHIH-HSIN YANG; Kuo W.-H; Chang D.-Y; Hsiung C.-N; Kuo K.-T; Chen W.-W |
| 臺大學術典藏 |
2020-05-25T07:35:36Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Cheng A.-L; Hsu C; Yang C.-H; Lu Y.-S; Chia-Chi Lin; Bu C.-F; Yeh K.-H.; Hsu C.-H |
| 臺大學術典藏 |
2020-05-25T07:35:34Z |
A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer
|
Chia-Chi Lin; Cheng A.-L; Hsu C.-H; Lu Y.-S; Hsu C; Yeh K.-H; Wu C.-Y; Huang C.-S; Yang C.-H. |
| 臺大學術典藏 |
2020-05-25T07:35:22Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Chia-Chi Lin; Su W.-C; Yen C.-J; Hsu C.-H; Su W.-P; Yeh K.-H; Lu Y.-S; Cheng A.-L; Huang D.C.-L; Fritsch H; Voss F; Taube T; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:38Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Chih-Hung Hsu;Cheng A.-L.;Hsu C.;Yang C.-H.;Lu Y.-S.;Lin C.-C.;Bu C.-F.;Yeh K.-H.; CHIH-HUNG HSU; Cheng A.-L.; Hsu C.; Yang C.-H.; Lu Y.-S.; Lin C.-C.; Bu C.-F.; Yeh K.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:37Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
CHIH-HUNG HSU; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Hsu C.;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Chih-Hung Hsu;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Hsu C.; Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H. |
| 臺大學術典藏 |
2020-04-28T07:25:35Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H.;Lu Y.-S.;Chih-Hung Hsu;Lin J.-F.;Hsu C.;Kuo S.-H.;Li Jr. S.;Cheng A.-L.; Yeh K.-H.; Lu Y.-S.; CHIH-HUNG HSU; Lin J.-F.; Hsu C.; Kuo S.-H.; Li Jr. S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:27Z |
Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma
|
Chiang C.-T.;Yeh P.-Y.;Gao M.;Chen C.-W.;Yeh L.-C.;Feng W.-C.;Kuo S.-H.;Chih-Hung Hsu;Lu Y.-S.;Cheng A.-L.; Chiang C.-T.; Yeh P.-Y.; Gao M.; Chen C.-W.; Yeh L.-C.; Feng W.-C.; Kuo S.-H.; CHIH-HUNG HSU; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:26Z |
Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001
|
Kuo S.-H.; CHIH-HUNG HSU; Chen L.-T.; Lu Y.-S.; Lin C.-H.; Yeh P.-Y.; Jeng H.-J.; Gao M.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. ;Chih-Hung Hsu ;Chen L.-T. ;Lu Y.-S. ;Lin C.-H. ;Yeh P.-Y. ;Jeng H.-J. ;Gao M. ;Yeh K.-H. ;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-28T07:25:19Z |
A phase i study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies
|
Lin C.-C.;Su W.-C.;Yen C.-J.;Chih-Hung Hsu;Su W.-P.;Yeh K.-H.;Lu Y.-S.;Cheng A.-L.;Huang D.C.-L.;Fritsch H.;Voss F.;Taube T.;Yang J.C.-H.; Lin C.-C.; Su W.-C.; Yen C.-J.; CHIH-HUNG HSU; Su W.-P.; Yeh K.-H.; Lu Y.-S.; Cheng A.-L.; Huang D.C.-L.; Fritsch H.; Voss F.; Taube T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-04-10T12:51:30Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma
|
Chiun Hsu;Huang C.-S.;Chao T.-Y.;Lu Y.-S.;Bu C.-F.;Chen M.M.;Chang K.-J.;Cheng A.-L.; Chiun Hsu; Huang C.-S.; Chao T.-Y.; Lu Y.-S.; Bu C.-F.; Chen M.M.; Chang K.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:29Z |
Phase II study of combination doxorubicin, interferon-α, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Li C.-C.; Kuo S.-H.; Yeh K.-H.; Yang C.-H.; Hsu C.-H.; Wu C.-Y.; Cheng A.-L.; Lu Y.-S.;Chiun Hsu;Li C.-C.;Kuo S.-H.;Yeh K.-H.;Yang C.-H.;Hsu C.-H.;Wu C.-Y.;Cheng A.-L.; Lu Y.-S.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-10T12:51:26Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'Ang H.-J.;Wang C.-C.;Cheng A.-L.;Chiun Hsu;Lu Y.-S.;Chang M.-C.;Lin J.-T.;Wang H.-P.;Shiah H.-S.;Liu T.-W.;Chang J.-Y.;Whang-Peng J.;Chen L.-T.; Ch'ang H.-J.; Wang C.-C.; Cheng A.-L.; Chiun Hsu; Lu Y.-S.; Chang M.-C.; Lin J.-T.; Wang H.-P.; Shiah H.-S.; Liu T.-W.; Chang J.-Y.; Whang-Peng J.; Chen L.-T. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma
|
Ou D.-L.; Shen Y.-C.; Liang J.-D.; Liou J.-Y.; Yu S.-L.; Fan H.-H.; Wang D.-S.; Lu Y.-S.; Chiun Hsu; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:21Z |
Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway
|
Chen K.-F.; Yeh P.-Y.; Chiun Hsu; Hsu C.-H.; Lu Y.-S.; Hsieh H.-P.; Chen P.-J.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:15Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
Cheng A.-L.; Hsu C.-H.; Lin Z.-Z.; Chiun Hsu; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Shao Y.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines
|
Chen W.-W.; Chang D.-Y.; Huang S.-M.; Lin C.-H.; Chiun Hsu; Lin M.-H.; Huang C.-S.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:51:13Z |
Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy
|
Kuo Y.-H.; Lin C.-H.; Shau W.-Y.; Chen T.-J.; Yang S.-H.; Huang S.-M.; Chiun Hsu; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:13Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
YU-YUN SHAO; Kuo K.-T.; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:12Z |
Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma
|
YU-YUN SHAO; Lin Z.-Z.; Hsu C.; Lee K.-D.; Hsiao C.-H.; Lu Y.-S.; Huang C.-C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:56Z |
Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS
|
Lu Y.-S.; Lin C.-H.; Tsai I.-L.; Kuo C.-H.; YU-YUN SHAO; Chiu H.-H.;Liao H.-W.;Yu-Yun Shao;Lu Y.-S.;Lin C.-H.;Tsai I.-L.;Kuo C.-H.; Chiu H.-H.; Liao H.-W. |
| 臺大學術典藏 |
2020-03-27T02:23:27Z |
O6-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers
|
Lin C.-H.; Cheng A.-L.; Tseng S.-H.; Tseng H.-M.; Wu P.-F.;Kuo K.-T.;Lu-Ting Kuo;Lin Y.-T.;Lee W.-C.;Lu Y.-S.;Yang C.-H.;Wu R.-M.;Tu Y.-K.;Tasi J.-C.;Tseng H.-M.;Tseng S.-H.;Cheng A.-L.;Lin C.-H.; Wu P.-F.; Kuo K.-T.; LU-TING KUO; Lin Y.-T.; Lee W.-C.; Lu Y.-S.; Yang C.-H.; Wu R.-M.; Tu Y.-K.; Tasi J.-C. |
| 臺大學術典藏 |
2020-03-27T02:03:49Z |
Pneumatosis coli after etoposide chemotherapy for breast cancer
|
Lu Y.-S.; Shih I.-L.; Shih I.-L.;Lu Y.-S.;Wang H.-P.;Kao-Lang Liu; Wang H.-P.; KAO-LANG LIU |
| 臺大學術典藏 |
2020-03-24T04:02:56Z |
The Association of Infrared Imaging Findings of the Breast with Hormone Receptor and Human Epidermal Growth Factor Receptor 2 Status of Breast Cancer
|
Wang J. ;Shih T.T.F. ;Yen R.-F. ;Lu Y.-S. ;Chen C.-Y. ;Mao T.-L. ;Lin C.-H. ;Wen-Hung Kuo ;Tsai Y.-S. ;Chang K.-J. ;Chien K.-L.; Wang J.; Shih T.T.F.; Yen R.-F.; Lu Y.-S.; Chen C.-Y.; Mao T.-L.; Lin C.-H.; WEN-HUNG KUO; Tsai Y.-S.; Chang K.-J.; Chien K.-L. |
